Joe Fletcher | SVP, IR |
David Ricks | Chairman, CEO & President |
Anat Ashkenazi | SVP & CFO |
Daniel Skovronsky | Chief Scientific and Medical Officer |
Anne White | SVP & President, Lilly Neuroscience |
Ilya Yuffa | SVP & President, Lilly International Lilly Research Labs |
Jake Van Naarden | SVP, CEO, Loxo Oncology & President, Lilly Oncology |
Michael Mason | SVP & President, Lilly Diabetes |
Christopher Schott | JPMorgan Chase & Co. |
Terence Flynn | Morgan Stanley |
Umer Raffat | Evercore ISI |
Stephen Scala | Cowen and Company |
Seamus Fernandez | Guggenheim Securities |
Robyn Karnauskas | Truist Securities |
Kerry Holford | Berenberg |
Timothy Anderson | Wolfe Research |
Louise Chen | Cantor Fitzgerald & Co. |
Colin Bristow | UBS |
Geoff Meacham | Bank of America Merrill Lynch |
David Risinger | SVB Securities |
Chris Shibutani | Goldman Sachs |
Andrew Baum | Citigroup |
Mohit Bansal | Wells Fargo Securities |
Evan Seigerman | BMO Capital Markets |
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q3 2022 Earnings Conference Call. [Operator Instructions]. And as a reminder, your conference is being recorded. I would now like to turn the conference over to your host, Joe Fletcher, Senior Vice President of Investor Relations. Please go ahead.